AT THE FRONTIERS IN CANCER RESEARCH: PROVIDING INSIGHTS AND FORGING COLLABORATIONS
Webinar: Unveiling the Dichotomous Role of STAT3 Signaling in Prostate Cancer
Dr. Lukas Kenner, Medical University of Vienna, presents his research on the ambiguous role of the STAT3 signaling pathway in prostate cancer progression and therapeutic potential. In the presented study, the TissueFAXS automated microscopy system was used to obtain whole slide images, and single cell quantification was performed with HistoQuest and StrataQuest.
Case Study: Spatial Analysis of CD4+ T-Cells in Colorectal Cancer
In Europe colorectal cancer was estimated as the second most common malignancy among new cancer cases, making it an important object of scientific immune-oncology research. The contextual image analysis software StrataQuest is an optimal tool for analyzing cell populations such as CD4+ T helper cells in their native tumor microenvironment.
Molecular Diagnostics Training School 2024
TissueGnostics is an Industrial Sponsor of MDTS 2024, organized by University of Nottingham and Medical University of Vienna on February 25-28 for medical professionals interested in methods and analysis approaches in molecular pathology and state of the art in diagnostics. Digital Pathology & Image Analysis Training School 2024 will continue on 29.02.-02.03.2024.
领英推荐
2nd International Conference on Microscopy Image Cytometry 2024
Dr. Nicolás E. Ottone, Universidad de La Frontera, Chile, organizes next meeting dedicated to the topics of tissue image cytometry and AI-powered spatial biology in health and disease. The conference will take place in October 21st-23rd 2024 in Pucon, Chile. Save the link below to stay up to date and secure a place for the conference in time.
Bridging Austrian Technology and Australian Scientists
As part of the prestigious REDI Fellowship through MTPConnect’s Researcher Exchange and Development Within Industry (REDI) initiative, Australian Prof. Jyotsna Batra, a leading expert in molecular genetics of prostate cancer, formally joined forces with Austrian company TissueGnostics for a two years project to develop a novel clinical in-situ test for prostate cancer precision diagnostics.